key: cord-1002072-xdjz4pt3 authors: Li, Jie; Wang, Jin-Lan; Zhang, Wen-Lu; Tu, Zeng; Cai, Xue-Fei; Wang, Yu-Wei; Gan, Chun-Yang; Deng, Hai-Jun; Cui, Jing; Shu, Zhao-Che; Long, Quan-Xin; Chen, Juan; Tang, Ni; Hu, Xue; Huang, Ai-Long; Hu, Jie-Li title: Protein sensors combining both on-and-off model for antibody homogeneous assay date: 2022-03-31 journal: Biosens Bioelectron DOI: 10.1016/j.bios.2022.114226 sha: 18fb81d220ddc84f5b7157d84bd108a3408335d6 doc_id: 1002072 cord_uid: xdjz4pt3 Protein sensors based on allosteric enzymes responding to target binding with rapid changes in enzymatic activity are potential tools for homogeneous assays. However, a high signal-to-noise ratio (S/N) is difficult to achieve in their construction. A high S/N is critical to discriminate signals from the background, a phenomenon that might largely vary among serum samples from different individuals. Herein, based on the modularized luciferase NanoLuc, we designed a novel biosensor called NanoSwitch. This sensor allows direct detection of antibodies in 1 μl serum in 45 min without washing steps. In the detection of Flag and HA antibodies, NanoSwitches respond to antibodies with S/N ratios of 33-fold and 42-fold, respectively. Further, we constructed a NanoSwitch for detecting SARS-CoV-2-specific antibodies, which showed over 200-fold S/N in serum samples. High S/N was achieved by a new working model, combining the turn-off of the sensor with human serum albuminand turn-on with a specific antibody. Also, we constructed NanoSwitches for detecting antibodies against the core protein of hepatitis C virus (HCV) and gp41 of the human immunodeficiency virus (HIV). Interestingly, these sensors demonstrated a high S/N and good performance in the assays of clinical samples; this was partly attributed to the combination of off-and-on models. In summary, we provide a novel type of protein sensor and a working model that potentially guides new sensor design with better performance. Protein sensors based on allosteric enzymes responding to target binding with 27 rapid changes in enzymatic activity are potential tools for homogeneous assays. 28 However, a high signal-to-noise ratio (S/N) is difficult to achieve in their construction. 29 A high S/N is critical to discriminate signals from the background, a phenomenon that 30 might largely vary among serum samples from different individuals. Herein, based on 31 the modularized luciferase NanoLuc, we designed a novel biosensor called NanoSwitch. antibody and in turn affect the associated bioluminescence activity (Fig. 1A) . The 205 alteration in luminescence reflected the number of antibodies in the reaction system. As expected, NanoSwitch-3xFlag responded to the Flag antibody, with a 3.9-fold 207 inhibition of the luminescence signal (Fig. 1B) . The sensor was optimized by 208 distributing 1xFlag tags to different positions to increase the S/N (Fig. 1C) . 209 Consequently, NanoSwitch-1xFlag-2NM, with two 1xFlag tags located on the two sides (Fig. 3F) . Thus, human serum albumin (HSA) was tested since it is the most 273 abundant protein in serum prone to binding many molecules (Rabbani and Ahn, 2019). As expected, HSA dose-dependently inhibited NanoSwitch-PG4-MC (Fig. 3G) . HSA 275 at a concentration equivalent to that in human serum (4 mg/ml) turned off the switch to 276 the same level as human serum (Fig. 3G) . Nevertheless, adding the PG4 peptide did not 277 inhibit the effect of HSA (Fig. 3H) , indicating that the binding of HSA to NanoSwitch-peptide from the X protein of hepatitis B virus), and even SmBiT-LgBiT were turned 281 off by HSA and human serum to different extents (Fig. 3I) . These results led to a 282 hypothesis that HSA in serum turned off NanoSwitch-PG4-MC, whereas SARS-CoV-283 2 antibodies turned it on majorly by releasing HSA. To further test this hypothesis, 284 NanoSwitch-PG4-MC was used to assay the rabbit multiclonal antibodies against a 285 peptide (SARS-CoV-2 spike protein amino acids 994-1218) that covers the PG4 286 sequence (spike amino acids 1141-1165). These antibodies slightly (< 2-fold) activated 287 the switch when HSA was not present in the system (Fig. 3J) . However, the addition of 288 HSA improved the S/N to approximately 30-fold (Fig. 3J) . Notably, 140 fM of the 289 antibodies triggered a greater fold-change in the HSA system than that which was 290 induced by 47 pM in the non-HSA system. A concern with NanoSwitch-PG4-MC detection is that the variation of HSA in Interestingly, we also noted that control serum samples reduced the NanoSwitch 319 signal by approximately 10-fold. We purified the immunoglobulin from a serum sample 320 with a positive HCV antibody using protein A affinity purification. The purified 321 immunoglobulin turned 77-fold on the NanoSwitch-HCV-core without HSA (Fig. 4C) . In contrast, adding control serum or HSA to the system augmented the response 323 amplitude of the NanoSwitch-HCV-core to 96-fold and 161-fold, respectively. This 324 indicates that a combination of off-and-on effects induced by HSA in serum improves 325 the S/N of the NanoSwitch-HCV-core in detection. Furthermore, we tested how HSA 326 affected the performance of NanoSwitch-HCV-core. HSA was introduced to the 327 appear satisfactory in the detection of antibodies, with S/Ns less than 10-fold. Also, 368 although we attempted this strategy on NanoLuc using an inhibitor peptide, it was 369 unsuccessful (unpublished data). The NanoSwitch developed in this study followed an alternative strategy. SmBiT Additionally, high S/Ns of a few NanoSwitches, particularly NanoSwitch-PG4- MC are attributed to a previously unreported off-and-on working model (Fig. 6) . By 384 careful investigation, we confirmed that HSA in serum is the substance turning off the 385 NanoSwitches. Of note, it is not strange that HSA with a high concentration interacting 386 with numerous molecules binds to NanoSwitches. This binding is partly associated with Protein engineering of antibody binding sites: 510 recovery of specific activity in an anti-digoxin single-chain Fv analogue Split-luciferase complementary assay of NLRP3 PYD-PYD interaction indicates 515 inflammasome formation during inflammation Glucose recognition proteins for glucose sensing at 518 physiological concentrations and temperatures Genetically Encoded Biosensors Based on 521 Fluorescent Proteins. Sensors (Basel) Engineering a regulatable enzyme for 523 homogeneous immunoassays Antibody 530 responses to SARS-CoV-2 in patients with COVID-19 Circularly permuted green fluorescent 533 proteins engineered to sense Ca2+ Two linear epitopes on the SARS-CoV-2 spike protein that elicit 548 neutralising antibodies in COVID-19 patients De 552 novo design of modular and tunable protein biosensors Structure, enzymatic activities, glycation and therapeutic potential 555 of human serum albumin: A natural cargo Synthetic protein switches: design principles and applications Design and development 560 of a whole-cell luminescent biosensor for detection of early-stage of apoptosis Bioluminescent Sensor Proteins for Therapeutic Drug Monitoring of Antitumor 564 Allosteric enzymes as biosensors for molecular diagnosis Age and sex variation in serum albumin 568 concentration: an observational study 2021. 573 A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies A biosensor for measuring NAD(+) levels at the point of care Responses of NanoSwitch-PG4-MC to the multiclonal antibodies in the presence of 617 different concentrations of HSA. * Note: Protein reaction buffer Methods) was used in Fig.3 F-K, and the reaction was carried out at pH 7.5 and 37°C